ROIV:NASDAQ, Roivant Sciences Ltd.
ROIV stock overview
Roivant Sciences Ltd. (ROIV:NASDAQ) closed at $34.70 on October 19, 2026,
up 3.49% on the day.
The stock trades 18.4% below its 52-week high of $42.50
and 100.8% above its 52-week low of $17.28.
Over the past year, it gained 95.6%.
Roivant Sciences Ltd. is part of the Health Care sector.
Key figures
- Price
- $34.70
- Day change
- +3.49%
- Volume
- 6,334,257
- Average volume
- 7,115,489
- Market cap
- 25B+
- 52-week range
- $17.28 – $42.50
- 50-day average
- $36.63
- 200-day average
- $30.79
Price action over the past year
In 252 trading sessions since October 17, 2025, ROIV closed higher on 130 days (52%).
Its best day was February 6, 2026 (+22.14%) and its worst was August 28, 2026 (-7.64%).
The stock moved 10% or more in a single session 3 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
ROIV news
-
Oct 19, 2026:
Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run
-
Oct 8, 2026:
IMVT, ROIV Stocks Slide As Argenx Sjögren's Trial Failure Hits Drug Class
-
Oct 8, 2026:
IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug Class
-
Sep 28, 2026:
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
-
Sep 24, 2026:
Roivant's Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?
-
Sep 23, 2026:
Roivant's Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
-
Sep 23, 2026:
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
-
Sep 22, 2026:
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
About Roivant Sciences Ltd.
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Similar stocks
Find more stocks like ROIV with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.